Skip to Content

'
E. Scott Kopetz, MD, PhD, FACP

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Regular Member Graduate Faculty, Graduate School of Biomedical Sciences, University of Texas Health Science Center, Houston, TX

Education & Training

Degree-Granting Education

2009 University of Texas, Graduate School of Biomedical Sciences, Houston, TX, PhD, Patient Oriented Biological Research/Cancer Biology
2001 Johns Hopkins School of Medicine, Baltimore, MD, MD, Medicine
1997 Vanderbilt University, Nashville, TN, BE, Summa Cum Laude, Biomedical Engineering/ Electrical Engineering

Postgraduate Training

7/2004-6/2006 Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Robert Wolff
7/2001-6/2004 Residency, Internal Medicine, Duke University Medical Center, Durham, NC, Diana McNeil

Board Certifications

10/2006 Medical Oncology
10/2004 Internal Medicine

Experience/Service

Other Appointments/Responsibilities

Member, NCI Colon Task Force, Bethesda, MD, 2012-present
Member, NCI Colon Task Force, Genomics Subcommittee, Bethesda, MD, 2012-present
Member, SWOG - Southwest Oncology Group, Ann Arbor, MI, 2012-present

Honors and Awards

2010-present Fellow, American College of Physicians
2010-2011 Gillson Longenbaugh Foundation Award, Gillson Longenbaugh Foundation
2006 The Del and Dennis McCarthy Endowed Fellowship for Gastrointestinal Cancer Research, The University of Texas MD Anderson Cancer Center
2004 Housestaff Leadership Award Recipient, Duke University Medical Center
2003 Professionalism Award, Duke University Medical School
1998 American Federation of Aging Research's Harvard Scholar, Johns Hopkins Medical School
1998 Harold Lamport Student Research Scholarship Recipient, Johns Hopkins Medical School
1997 Summa Cum Laude, Vanderbilt University
1993-1997 Harold Sterling Vanderbilt Scholar, Vanderbilt University

Selected Publications

Peer-Reviewed Original Research Articles
1. Andreou A, Aloia TA, Brouquet A, Dickson PV, Zimmitti G, Maru DM, Kopetz ES, Loyer EM, Curley SA, Abdalla EK, Vauthey JN. Margin Status Remains an Important Determinant of Survival After Surgical Resection of Colorectal Liver Metastases in the Era of Modern Chemotherapy. Ann Surg. e-Pub 2/2013. PMID: 23426338.
2. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz ES. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with P13K inhibition or demethylating agents. Clinical Cancer Research 19(3):657-667, 2/2013. e-Pub 12/2012. PMID: 23251002.
3. Clary BM, Grothey A, Kopetz ES, Marsh RD. Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement. HPB (Oxford) 15(2):116-8, 2/2013. PMID: 23297722.
4. Davies MA, Kopetz ES. Overcoming Resistance to MAPK Pathway Inhibitors. J Natl Cancer Inst 105(1):9-10, 1/2013. e-Pub 12/2012. PMID: 23250957.
5. Overman MJ, Modak J, Kopetz ES, Murthy R, Yao JC, Hicks ME, Abbruzzese JL, Tam AL. Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed? J Clin Oncol 31(1):17-22, 1/2013. e-Pub 11/2012. PMID: 23129736.
6. Shindoh J, Loyer EM, Kopetz ES, Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA, Vauthey JN. Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic Colorectal Metastases. J Clin Oncol 30(36):4566-72, 12/2012. e-Pub 11/2012. PMID: 23150701.
7. Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz ES, Win S, Kurzrock R. Outcomes in 144 Patients With Colorectal Cancer Treated in a Phase I Clinic: the MD Anderson Cancer Center Experience. Clin Colorectal Cancer 11(4):297-303, 12/2012. e-Pub 4/2012. PMID: 22537607.
8. Andreou A, Kopetz ES, Maru DM, Chen SS, Zimmitti G, Brouquet A, Shindoh J, Curley SA, Garrett C, Overman MJ, Aloia TA, Vauthey JN. Adjuvant Chemotherapy With FOLFOX for Primary Colorectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepatectomy for Metachronous Liver Metastases. Ann Surg 256(4):642-50, 10/2012. e-Pub 9/2012. PMID: 22968062.
9. Galon J, Franck P, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Hartmann A, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz ES, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 10(1):205, 10/2012. PMID: 23034130.
10. Morelli MP, Kopetz ES. Hurdles and Complexities of Codon 13 KRAS Mutations. J Clin Oncol 30(29):2565-7, 10/2012. e-Pub 8/2012. PMID: 22927534.
11. Vauthey JN, Kopetz ES, Aloia TA, Andreou A. KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary. Br J Cancer 107(8):1442-3, 10/2012. e-Pub 9/2012. PMID: 23018559.
12. Kopetz ES, Lemos R, Powis G. The Promise of Patient-Derived Xenografts: The best laid plans of mice and men. Clin Cancer Res 18(19):5160-2, 10/2012. e-Pub 8/2012. PMID: 22912394.
13. Ferrarotto R, Machado K, Mak MP, Shah N, Takahashi TK, Costa FP, Overman MJ, Kopetz ES, Hoff PM. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. Eur J Cancer 48(6):820-6, 4/2012. e-Pub 2/2012. PMID: 22330318.
14. Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcox ME, Kopetz ES, Heimbrook D, Lestini B, Bollag G, Su F. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res. e-Pub 12/2011. PMID: 22180495.
15. Boonsirikamchai P, Asran MA, Maru DM, Vauthey JN, Kaur H, Kopetz ES, Loyer EM. CT Findings of Response and Recurrence, Independent of Change in Tumor Size, in Colorectal Liver Metastasis Treated With Bevacizumab. AJR Am J Roentgenol 197(6):W1060-6, 12/2011. PMID: 22109320.
16. Brouquet A, Overman MJ, Kopetz ES, Maru DM, Loyer EM, Andreou A, Cooper A, Curley SA, Garrett CR, Abdalla EK, Vauthey JN. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Cancer 117(19):4484-92, 10/2011. e-Pub 3/2011. PMCID: PMC3128184.
17. Oh SC, Park YY, Park ES, Lim JY, Kim SM, Kim SB, Kim J, Kim SC, Chu IS, Smith JJ, Beauchamp RD, Yeatman TJ, Kopetz ES, Lee JS. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut. e-Pub 10/2011. PMID: 21997556.
18. Ferrarotto R, Pathak P, Maru D, Agarwal A, Overman M, Hoff PM, Kopetz ES. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer 10(3):178-82, 9/2011. e-Pub 4/2011. PMID: 21855039.
19. George B, Kopetz ES. Predictive and Prognostic Markers in Colorectal Cancer. (Invited). Curr Oncol Rep 13(3):206-15, 6/2011. e-Pub 3/2011. PMID: 21373987.
20. Fogelman DR, Wolff RA, Kopetz ES, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL. Evidence for the Efficacy of Iniparib, a PARP-1 Inhibitor, in BRCA2-associated Pancreatic Cancer. Anticancer Res 31(4):1417-20, 4/2011. PMID: 21508395.
21. Brouquet A, Abdalla EK, Kopetz ES, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 29(8):1083-90, 3/2011. e-Pub 1/2011. PMCID: PMC3068054.
22. Tran B, Kopetz ES, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. e-Pub 3/2011. PMID: 21456008.
23. Ihle NT, Powis G, Kopetz ES. PI-3-Kinase Inhibitors in Colorectal Cancer (Peer-reviewed Review). Curr Cancer Drug Targets 11(2):190-8, 2/2011. e-Pub 12/2010. PMID: 21158718.
24. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz ES, McConkey DJ, Evans DB, Gallick GE. ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma. PLoS One 6(6):e20636, 2011. e-Pub 6/2011. PMCID: PMC3113804.
25. Maru DM, Kopetz S, Boonsirikamchai P, Agarwal A, Chun YS, Wang H, Abdalla EK, Kaur H, Charnsangavej C, Vauthey JN, Loyer EM. Tumor Thickness at the Tumor-normal Interface: A Novel Pathologic Indicator of Chemotherapy Response in Hepatic Colorectal Metastases. Am J Surg Pathol 34(9):1287-1294, 9/2010. e-Pub 8/2010. PMID: 20697255.
26. Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, Motta M, Ravarino N, Risio M, Curley SA, Abdalla EK, Capussotti L, Vauthey JN. Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases. Ann Surg Oncol 17(11). e-Pub 6/2010. PMID: 20567921.
27. Silberfein EJ, Kattepogu KM, Hu CY, Skibber JM, Rodriguez-Bigas MA, Feig B, Das P, Krishnan S, Crane C, Kopetz S, Eng C, Chang GJ. Long-term Survival and Recurrence Outcomes Following Surgery for Distal Rectal Cancer. Annals of Surgical Oncology 17(11):2863-9, 6/2010. PMID: 20552409.
28. Brouquet A, Mortenson MM, Vauthey JN, Rodriguez-Bigas MA, Overman MJ, Chang GJ, Kopetz S, Garrett C, Curley SA, Abdalla EK. Surgical Strategies for Synchronous Colorectal Liver Metastases in 156 Consecutive Patients: Classic, Combined or Reverse Strategy? J Am Coll Surg 210(6):934-41, 6/2010. PMID: 20510802.
29. Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA. Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol 49(4):474-9, 5/2010. PMID: 20397775.
30. Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, Eng C, Hoff PM, Vauthey JN, Wolff RA, Kopetz S. Oxaliplatin-Mediated Increase in Spleen Size As a Biomarker for the Development of Hepatic Sinusoidal Injury. J Clin Oncol 28(15):2549-2555, 4/2010. PMID: 20406923.
31. Lieu C, Kopetz S. The SRC family of protein tyrosine kinases: A new and promising target for colorectal cancer therapy. (Peer-reviewed Review). Clin Colorectal Cancer 9(2):89-94, 4/2010. PMID: 20378502.
32. Vauthey JN, Nordlinger B, Kopetz S, Poston G. Sequenced Chemotherapy and Surgery for Potentially Resectable Colorectal Liver Metastases: A Debate Over Goals of Research and an Approach While the Jury Remains Out. Ann Surg Oncol 17(8):1983-1986, 3/2010. PMID: 20232164.
33. Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer 102(1):144-50, 01/05/2010, 1/2010. PMID: 19935793.
34. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. Journal of Clinical Oncology 28(3):453-9, 1/2010. PMID: 20008624.
35. Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, Curley SA, Abdalla EK, Charnsangavej C, Loyer EM. Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases. JAMA 302(21):2338-2344, 12/2009. PMID: 19952320.
36. Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, Coulson RL, Charnsangavej C, Vauthey JN, Wolff RA, Kopetz S. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 8(4):225-30, 10/2009. PMID: 19822514.
37. Kopetz S, Chang G, Overman M, Eng C, Larson DW, Grothey A, Vauthey JN, Sargent D, McWilliams R. Improved Survival in Metastatic Colorectal Cancer is Associated with Sequential Adoption of Hepatic Resection and Improved Chemotherapy. J Clin Oncol 27(22):3677-83, 8/2009. e-Pub 5/2009. PMCID: PMC2720081.
38. Herman MP, Kopetz S, Bhosale PR, Eng C, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Delclos ME, Krishnan S, Crane CH, Das P.. Sacral Insufficiency Fractures After Preoperative Chemoradiation for Rectal Cancer: Incidence, Risk Factors, and Clinical Course. Int J Radiat Oncol Biol Phys 74(3):818-23, 7/2009. e-Pub 1/2009. PMID: 19147305.
39. Rossi S, Kopetz S, Davuluri R, Hamilton SR, Calin GA. MicroRNAs, ultraconserved genes and colorectal cancers. (Invited). Int J Biochem Cell Biol 42(8):1291-1297, 6/2009. e-Pub 6/2009. PMID: 19497386.
40. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. J Clin Oncol 26(15S):4538, 6/2009. e-Pub 1/2009. PMID: 19164203.
41. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE.. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69(9):3842-9, 5/2009. e-Pub 4/2009. PMCID: PMC2709758.
42. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 16(3):614-22, 3/2009. e-Pub 1/2009. PMID: 19130139.
43. Kim MP, Park SI, Kopetz S, Gallick GE.. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res 1(335):249-59, 1/2009. e-Pub 9/2008. PMID: 18815812.
44. Chang DZ, Kumar V, Ma Y, Li K, Kopetz S. Individualized Therapies in Colorectal Cancer: KRAS as a Marker for Response to EGFR-targeted Therapy (Invited Editorial). J Hematol Oncol 2(18):18, 2009. e-Pub 4/2009. PMCID: PMC2686726.
45. Fogelman DR, Kopetz S, Eng C. Emerging Drugs for Colorectal Cancer (Invited). Expert Opin Emerg Drugs 13(4):629-42, 12/2008. PMID: 19046131.
46. Blazer DG, Kish U, Maru DM, Kopetz S, Overman M, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover K, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point after Resection of Hepatic Colorectal Metastases. J Clin Oncol 59(33):5344-51, 11/2008. e-Pub 10/2008. PMID: 18936472.
47. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, Curley SA, Feig BW. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26(32):5254-60, 11/2008. e-Pub 10/2008. PMID: 18854565.
48. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 113(8):2038-45, 10/2008. PMID: 18759326.
49. Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest 26(8):794-9., 10/2008. PMID: 18798063.
50. Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbrizzese JL. Phase I study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest. New Drugs 26(5), 10/2008. e-Pub 6/2008. PMID: 18528634.
51. Hoff PM, Kopetz S, Thomas MB, Langleben A, Rinaldi D, Anthony L, Wolff RA, Lassere Y, Abbruzzese JL. A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. Br J Cancer 99(5):722-6, 9/2008. e-Pub 8/2008. PMID: 18728662.
52. Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla EK, Pisters P, Kopetz S, Eng C, Wolff RA. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer 7(5):338-42, 9/2008. PMID: 18794067.
53. Kauffman CR, Mahvash A, Kopetz S, Wolff RA, Ensor J, Wallace MJ. Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy. Cancer 14(10):2283-8, 5/2008. PMID: 18344210.
54. Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C. Systematic Survey of Therapeutic Trials for Metastatic Colorectal Cancer: Room for Improvement in the Critical Pathway. J Clin Oncol 26(12):2000-5, 4/2008. PMID: 18421052.
55. Kopetz S, Freitas D, Calabrichi A, Hoff PM. Adjuvant Chemotherapy for Stage II Colon Cancer (Peer-Reviewed Review). Oncology 22(3):260-70, 3/2008. PMID: 18494354.
56. Dhillon N, Kopetz S, Pei BL, Fabbro ED, Zhang T, Bruera E. Clinical findings of a palliative care consultation team at a comprehensive cancer center. J Palliat Med 11(2):191-7, 3/2008. PMID: 18333733.
57. Politano S, Overman M, Pathak P, Chadha R, Glover K, Chang DZ, Wolff RA, Hoff PM, Abbruzzese J, Eng C, Kopetz S. Second-Line Chemotherapy Use in Metastatic Colon Cancer Varies by Disease Responsiveness. Clin Colorectal Cancer 1(1):55-9, 1/2008. PMID: 18279578.
58. Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, Curley SA, Abdalla EK. Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival. J Gastrointest Surg 11(11):1498-1505, 11/2007. e-Pub 9/2007. PMID: 17849166.
59. Kopetz S, Jimenez C, Tu SM, Sharma P. Pulmonary arteriovenous fistula in a patient with renal cell carcinoma. Eur Respir J 29(4):813-5, 12/2006. PMID: 17400880.
60. Kopetz S. Endothelin-1 as a Target For Therapeutic Intervention in Prostate Cancer (Invited). Invest New Drugs 20:173-82, 5/2002. PMID: 12099577.
61. Kopetz ES, TH Magnuson, MD Duncan, JS Bender, KD Lillemoe, TA Gordon, JL Cameron, JW Harmon. Complications of neglected cholelithiasis account for significant surgical mortality in the elderly. Surg Forum(52):489-91, 10/2000.
62. Kopetz S, Steele CD, Brandt J, Baker A, Kronberg M, Galik E, Steinberg M, Warren A, Lyketsos CG. Characteristics and outcomes of dementia residents in an assisted living facility. Int J Geriatr Psychiatry 15(7):586-93, 7/2000. PMID: 10918338.
63. Cheng MD, Nash TM, Kopetz ES. Retrieval of Aerosol Optical Thickness by Means of the Least-Median-Squares Robust Algorithm. Journal of Aerosol Science 30:805-17, 1/1999.
64. Walczak WJ, Xiao JM, Kopetz ES, Lease K, Grau H, Lee SP, Han MK, and Knutson JR. Golden Ruler: Very Long-Range Resonance Energy Transfer to Surface Plasmon Acceptors. Biophysical Journal, 72:367, 2/1997.

Invited Articles
1. Kopetz S. Novel Targets for Systemic Therapy of Colorectal Cancer. Clin Adv Hematol Oncol 6(1):38-40, 1/2008. PMID: 18322439.
2. Kopetz S, Shah AN, Gallick GE. SRC continues aging: current and future clinical directions. Clin Cancer Res 13(24):7232-6, 12/2007. PMID: 18094400.
3. Kopetz S. Targeting Src and Epidermal Growth Factor Receptor in Colorectal Cancer: Rationale and Progress Into the Clinic. Gastrointestinal Cancer Research 1:S37-41, 7/2007.
4. Kopetz S, Hoff PM. Cytotoxic chemotherapy for advanced colorectal cancer. Recent advances in management. Oncology (Williston Park) 19(13 Suppl 6):11-7, 11/2005. PMID: 16502665.
5. Kopetz S, Kim ES. Adjuvant Chemotherapy in Non-Small Cell Lung Cancer. American Journal of Oncology Review (Pulmonary Supplement):1-4, 2/2005.

Editorials
1. Kopetz S, Vauthey JN. Perioperative chemotherapy for resectable hepatic metastases. Lancet 371(9617):963-5, 3/2008. PMID: 18358910.
Other Articles
1. Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis. Clin Cancer Res 17(19):6130-9, 10/1/2011. e-Pub 9/27/2011. PMID: 21953501.

Abstracts
1. Chang G, Maru D, Agarwal A,Schlette E, Wolff R, Rodriguez-Bigas M, You N, Feig B, Kopetz S, Skibber J, Eng C. Histopathologic responses in primary tumors of patients with metastatic colorectal carcinoma after neoadjuvant systemic chemotherapy alone. 12th World Congress on Gastrointestinal Cancer, 6/2010.
2. Chang G, Maru D, Agarwal A, Schlette E, Wolff R, Rodriguez-Bigas M, You N, Feig B, Kopetz S, Skibber J, Eng C. Histopathologic responses in primary tumors of patients with metastatic colorectal carcinoma after neoadjuvant systemic chemotherapy alone. Annals of Oncology, 6/2010.
3. Kopetz S, Wu J, Davies M, Parikh N, Johnson F, Gallick G, Donato N. Synergistic activity of Src and EGFR inhibitors in colon cancer. AACR Annual Meeting (#4079), 2007.

Book Chapters
1. Kopetz S. Targeted Therapy in Cancer. In: Targeted Therapy for Colorectal Cancer. Ed(s) Razelle Kurzrock, Maurie Markman. Humana Press: United States, 101-24, 2008. ISBN: 978-1-60327-423-4.
2. Kopetz S, Raber M, Abbruzzese J. Colorectal, Anal, and Unknown Primary Cancer (electronic web update). In: Cancer Medicine, 2006.

Letters to the Editor
1. Vauthey JN, Zorzi D, Kopetz S, Abdalla EK, Kishi Y, Blazer DG. Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival Reply. J Clin Oncol 27(20):E20-E21, 7/2009.
2. Vauthey JN, Zorzi D, Kopetz S, Abdalla EK, Kishi Y, Blazer DG, III. Reply to Colorectal hepatic metastases: adjuvant chemotherapy and survival by D. Gallagher et al. J Clin Oncol 27(20):e20-1, 7/2009.
3. Kopetz S, Abbruzzese JL.. Hidden Biases in an Observational Study of Bevacizumab Beyond Progression. J Clin Oncol 27(10):1732-3, 4/2009. e-Pub 3/2009. PMID: 19255299.
4. Overman M, Kopetz S. First-Line Therapeutic Strategies in Metastatic Colorectal Cancer The Davies/Goldberg Article Reviewed. Oncology, New York-New York 22(13):1482-1483, 11/2008.

Grant & Contract Support

Title: Classification and mechanism of cetuximab acquired resistance in colorectal cancer
Funding Source: UT MD Anderson Cancer Center
Role: Principal Investigator
Duration: 1/1/2013 - 12/31/2014
 
Title: Integrating Genomics and epigenomics in Stage II and III Colon Cancer: Colon Cancer Integromics.
Funding Source: UT MD Anderson Cancer Center - Hogan Award
Role: Principal Investigator
Duration: 7/1/2011 - 6/30/2013
 
Title: PTEN-loss enriched Akt inhibition clinical study in colorectal cancer
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 5/1/2011 - 4/30/2014
 
Title: Bevacizumab Modulation of Radiographic Response and Oxaliplatin-Associated Hepatic Toxicity
Funding Source: Roche
Role: Principal Investigator
Duration: 5/1/2011 - 4/30/2014
 
Title: Colorectal Cancer Expansion Cohort Correlative Analysis
Funding Source: Plexxicon
Role: Principal Investigator
Duration: 3/1/2011 - 1/31/2014
 
Title: Evaluation of VEGF-C and VEGF-D in Patients with Metastatic Colorectal Cancer
Funding Source: Circadian Technologies Limited
Role: Principal Investigator
Duration: 2/1/2010 - 2/28/2013
 
Title: Investigator Initiated - Phase II study of second-line irinotecan plus brivanib, a dual tyrosine inhibitor of VEGFR and FGFR, in metastatic colorectal cancer patients enriched for elevated levels of plasma FGF following progression on bevacizumab-based treatment, Protocol
Funding Source: Bristol-Myers Squibb
Role: Co-Principal Investigator
Principal Investigator: Kopetz/Overman
Duration: 2010 - present
 
Title: Preclinical strategies for selection of patients with metastatic colon cancer susceptible to AZD0530 in combination with chemotherapy, Protocol
Funding Source: AstraZeneca
Role: Co-Principal Investigator
Principal Investigator: Gary Gallick
Duration: 9/1/2009 - 9/30/2013
 
Title: MicroRNAs and other non-coding RNAs in colorectal metastasis, R01, Protocol
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Calin/Hamilton/Kopetz
Duration: 6/8/2009 - 6/30/2011
 
Title: Src Inhibition in Colorectal Cancer, K23, Protocol
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2008 - 8/30/2013
 
Title: Career Development Award-Reversing Oxaliplatin Resistance with a Src Inhibitor in Colorectal Cancer, Protocol
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 7/1/2008 - 6/30/2011
 
Title: Phase I study of two week TAS-109 (nucleoside analogue), Protocol
Funding Source: Taiho
Role: Principal Investigator
Duration: 7/6/2006 - 3/31/2008
 
Title: K12, Paul Calabresi Career Development Award for Clinical Oncology (Fellow: 2006-07, Faculty 2007-08), Protocol
Funding Source: NIH/NCI
Role: Investigator
Duration: 9/1/2005 - 8/30/2008

Last updated: 3/7/2013